Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data
Longitudinal real-world data can enhance assessment of 2L therapy effectiveness. After confounder adjustment, we found clinically meaningful survival differences by 2L choice. These findings underscore the importance of 2L treatment selection and the need for prospective validation.
Authors
- Gary Hettinger (ORCID: https://orcid.org/0000-0001-5980-2946)
- Ravi B. Parikh
- Qi Long
Institutions
- Emory University (US)
- New York University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Clinical Lung Cancer
- Published
- 2025-09-27
- DOI
- https://doi.org/10.1016/j.cllc.2025.09.010
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00